Interleukin-23 Antagonist [EPC]

75099 reported adverse events

Drugs of this class: GUSELKUMAB TILDRAKIZUMAB-ASMN USTEKINUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-23 Antagonist [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 9722
1 OFF LABEL USE 7149
2 PSORIASIS 5893
3 PRODUCT DOSE OMISSION ISSUE 4579
4 PRODUCT USE ISSUE 3868
5 FATIGUE 3080
6 CROHN^S DISEASE 3062
7 PAIN 2844
8 ARTHRALGIA 2816
9 HEADACHE 2676
See all common reactions for Interleukin-23 Antagonist [EPC]

Drugs of the Interleukin-23 Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 RED BLOOD CELL SEDIMENTATION RATE 109 0.5477
1 SWOLLEN JOINT COUNT INCREASED 272 0.5323
2 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 1070 0.4142
3 RHEUMATIC FEVER 316 0.4083
4 RHEUMATOID FACTOR POSITIVE 964 0.3752
5 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY 32 0.3678
6 CONTRAINDICATION TO VACCINATION 41 0.2426
7 ENTHESOPATHY 230 0.2224
8 PITYRIASIS RUBRA PILARIS 28 0.2105
9 DUODENAL ULCER PERFORATION 482 0.2038
See all enriched reactions for Interleukin-23 Antagonist [EPC]